Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes Read more →

Iambic maintains momentum from string of Big Pharma partnerships by aiming for IPO Read more →

White House plans to put NIH grants under political control: reports Read more →